title: Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502.
abstract: OBJECTIVE
  Evaluation of the effects of an experimental long-acting non-ergot dopamine agonist, CV 205-502, on serum prolactin, tumor size, gonadal function, visual abnormalities, and tolerability in patients with macroprolactinomas.
  
  
  METHODS
  Prospective, unblinded, dose escalation as needed.
  
  
  METHODS
  Four university medical centers; patients referred for treatment.
  
  
  METHODS
  Twenty-six hyperprolactinemic patients (prolactin greater than 150 micrograms/L) with a pituitary macroadenoma were treated for 24 weeks with CV 205-502 given once daily.
  
  
  RESULTS
  Serum prolactin was measured at regular intervals. Prolactin levels decreased in all patients during treatment (mean pretreatment level, 2051.7 +/- 1077 micrograms/L [+/- SE]; 24 weeks, 39.0 +/- 11.3 micrograms/L; P = 0.0001); normal prolactin levels were achieved in 15 (58%). Tumor size decreased in 21 of 26 patients and ranged from 6% to 67% (mean, 19.2% +/- 3.4%). Onset or return of regular menses occurred in 11 of 15 premenopausal women, accompanied by an increase in estradiol concentrations (pretreatment, 186.5 +/- 25.0 pmol/L; on treatment, 690.9 +/- 104.3 pmol/L; P = 0.0003). Serum testosterone increased in 6 of 8 men; sexual function improved in 5 of 7 with pretreatment abnormalities. Two patients with reversible visual abnormalities improved within 2 weeks of starting treatment. Side effects occurred in 11 patients and abated over 1 to 2 weeks or after the dose was reduced. There was no evidence of toxicity as indicated by serial serum chemistries, liver function tests, hematologic profiles, thyroxine levels, and electrocardiogram studies.
  
  
  CONCLUSIONS
  CV 205-502 reverses hyperprolactinemia and promotes reduction in tumor size with reversal of visual abnormalities and restoration of gonadal function in most patients. This compound will probably be useful in treating prolactinomas.
authors.affiliation: University of Virginia Health Sciences Center, Charlottesville.
authors.forename: M L
authors.initials: ML
authors.lastname: Vance
authors.forename: M
authors.initials: M
authors.lastname: Lipper
authors.forename: A
authors.initials: A
authors.lastname: Klibanski
authors.forename: B M
authors.initials: BM
authors.lastname: Biller
authors.forename: N A
authors.initials: NA
authors.lastname: Samaan
authors.forename: M E
authors.initials: ME
authors.lastname: Molitch
mesh_terms: D000236:Adenoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000634:Aminoquinolines / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy; D005260:Female; D006801:Humans; D007989:Libido / Q000187:drug effects; D008279:Magnetic Resonance Imaging; D008297:Male; D008597:Menstrual Cycle / Q000187:drug effects; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011388:Prolactin / Q000009:adverse effects / Q000097:blood / Q000378:metabolism*
chemical_list: D000634:Aminoquinolines; D015259:Dopamine Agents; C046650:quinagolide; D011388:Prolactin